文献速递胸部肿瘤放疗放疗物理与技术

使用肺和心脏的有效α/β预测接受质子束治疗的非小细胞肺癌患者的放射性肺炎

Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy.
PubMed 文献 · Radiother Oncol · 2023-11-14

该研究回顾性分析两个国际中心96例接受被动散射质子治疗同步化疗的非小细胞肺癌患者,随机分为训练集64例和验证集32例,评估基于肺和心脏有效α/β的模型预测≥2级放射性肺炎。训练集中肺-GTV生物有效剂量单因素及联合心脏有效α/β的多因素模型有统计学意义,但验证集中未验证;其性能与基于平均肺剂量和心脏V20Gy的模型相似。结论认为光子放射化疗的预测模型仍适用于被动散射质子治疗患者。

要点

  • 训练集中肺-GTV生物有效剂量单因素模型预测≥2级放射性肺炎有统计学意义(p=0.019,AUC=0.72)。
  • 联合心脏有效α/β的多因素模型在训练集有统计学意义(pBED=0.006,AUC=0.74),但验证集AUC仅0.50。
  • 基于平均肺剂量和心脏V20Gy的模型与有效α/β模型性能相似,验证集AUC分别为0.51和0.53。

核心结论

  • 使用肺和心脏的有效α/β参数预测≥2级放射性肺炎的性能与常用的光子治疗模型(如平均肺剂量)相似。
  • 为光子放射化疗开发的预测模型仍适用于接受被动散射质子治疗的非小细胞肺癌患者。

研究设计与样本

  • 回顾性分析两个国际中心前瞻性临床研究中96例接受被动散射质子治疗同步化疗的非小细胞肺癌患者的数据。
  • 数据随机分为训练集64例和验证集32例,采用二项逻辑回归进行统计分析。

主要发现

  • 训练集中肺-GTV生物有效剂量单因素模型预测≥2级放射性肺炎有统计学意义(p=0.019,AUCtrain=0.72)。
  • 训练集中肺-GTV生物有效剂量联合心脏有效α/β的多因素模型有统计学意义(pBED=0.006,心脏有效α/β的p=0.043,AUCtrain=0.74)。
  • 上述模型在验证集中未验证(AUCval分别为0.52和0.50)。
  • 基于平均肺剂量的模型在训练集有统计学意义(p=0.015,AUCtrain=0.73),验证集AUCval=0.51。
  • 联合心脏V20Gy的多因素模型中平均肺剂量p=0.039,心脏V20Gy p=0.58,AUCtrain=0.74,AUCval=0.53。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation pneumonitis (RP) remains a major complication in non-small cell lung cancer (NSCLC) patients undergoing radiochemotherapy (RCHT). Traditionally, the mean lung dose (MLD) and the volume of the total lung receiving at least 20 Gy (V20Gy) are used to predict RP in patients treated with normo-fractionated photon therapy. However, other models, including the actual dose-distribution in the lungs using the effective α/β model or a combination of radiation doses to the lungs and heart, have been proposed for predicting RP. Moreover, the models established for photons may not hold for patients treated with passively-scattered proton therapy (PSPT). Therefore, we here tested and validated novel predictive parameters for RP in NSCLC patient treated with PSPT. METHODS: Data on the occurrence of RP, structure files and dose-volume histogram parameters for lungs and heart of 96 NSCLC patients, treated with PSPT and concurrent chemotherapy, was retrospectively retrieved from prospective clinical studies of two international centers. Data was randomly split into a training set (64 patients) and a validation set (32 patients). Statistical analyses were performed using binomial logistic regression. RESULTS: The biologically effective dose (BED) of the'lungs - GTV' significantly predicted RP ≥ grade 2 in the training-set using both a univariate model (p = 0.019, AUCtrain = 0.72) and a multivariate model in combination with the effective α/β parameter of the heart (pBED = 0.006, [Formula: see text] = 0.043, AUCtrain = 0.74). However, these results did not hold in the validation-set (AUCval = 0.52 andAUCval = 0.50, respectively). Moreover, these models were found to neither outperform a model built with the MLD (p = 0.015, AUCtrain = 0.73, AUCval = 0.51), nor a multivariate model additionally including the V20Gy of the heart (pMLD = 0.039, pV20Gy,heart = 0.58, AUCtrain = 0.74, AUCval = 0.53). CONCLUSION: Using the effective α/β parameter of the lungs and heart we achieved similar performance to commonly used models built for photon therapy, such as MLD, in predicting RP ≥ grade 2. Therefore, prediction models developed for photon RCHT still hold for patients treated with PSPT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Weiß A, Löck S, Xu T, et al. Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy. Radiother Oncol. 2023. PMID: 37972734. doi:10.1016/j.radonc.2023.110013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。